Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

(Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

U.S. President-elect Donald Trump will not go to jail or face any other punishment for his criminal conviction stemming from hush money paid to a porn star, a judge ruled on Friday but said Trump ...

But we'll be back tomorrow with more updates on the war in Ukraine. Here are the key lines from today: Outgoing US defence secretary Lloyd Austin announced a $500m (£407m) aid package for Ukraine ...

The Service Employees International Union, which represents nearly 2 million workers in industries like home health care and janitorial services, said Wednesday that it would become part of the ...

Political leaders have shunned the Alternative for Germany. But on his social media platform X, Mr. Musk is pitching the party as mainstream. By Jim Tankersley Pierre Poilievre, the Conservative ...

Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...

Across China’s west, the Communist Party is placing children in boarding schools to assimilate a generation of Tibetans into the national mainstream and mold them into loyal citizens. By Chris ...